Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Gefitinib and Docetaxel in Advanced Pancreatic Carcinoma
NCT00177242Phase 2Completed
- Sponsor
- University of Pittsburgh
- Start
- Sep 2004
- Modality
- Small Molecules
- Countries
- 1
01
Overview
Phase 2, open-label, single-arm trial of gefitinib in pancreatic carcinoma, sponsored by University of Pittsburgh. Primary endpoint: Median Overall Survival. Started Sep 2004; status: completed.
02
Drugs
03
Conditions
pancreatic carcinoma
Beyond the preview
Go deeper on NCT00177242.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT00177242.